Drugs / PRS-220
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05473533 | Oct 2022 → Aug 2023 | — | Pieris Australia Pty Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRS-220 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05473533 ↗ |
| Route | Inhaled | “PRS-220 administered by oral inhalation” NCT05473533 ↗ |